{"disease":{"id":"primary-focal-segmental-glomerulosclerosis","name":"primary focal segmental glomerulosclerosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT06315504","title":"Circulating Factors in Nephrotic Syndrome","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Iain Bressendorff","has_results":false},{"nct_id":"NCT02921789","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03422510","title":"FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Complexa, Inc.","has_results":false},{"nct_id":"NCT04983888","title":"Obinutuzumab in Primary FSGS","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}